Skip to main
ALLO
ALLO logo

ALLO Stock Forecast & Price Target

ALLO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allogene Therapeutics Inc is demonstrating a positive outlook driven by its strategic pivot to standard FC lymphodepletion in the ALPHA3 trial, prioritizing patient safety and simplifying clinical protocols. The company has captured over 90% patient consent for minimal residual disease (MRD) screening, with positivity rates indicating a substantial patient pool for potential enrollment, ensuring robust ongoing research and development. Positive feedback from investigators regarding the regimen simplification further supports the potential for enhanced real-world adoption of Allogene's therapies, mitigating complexities and associated infection risks.

Bears say

Allogene Therapeutics Inc faces substantial risks associated with the approval processes for their clinical-stage products, with potential delays or failures in achieving regulatory approval likely to adversely affect the company's share price. Additionally, the inherent uncertainties of clinical trials raise concerns about the efficacy and safety of Allogene's assets, which may fail to meet necessary standards in current or future evaluations. Furthermore, the company faces significant regulatory and commercial risks that pose additional challenges to its operational and financial stability.

ALLO has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allogene Therapeutics Inc (ALLO) Forecast

Analysts have given ALLO a Buy based on their latest research and market trends.

According to 9 analysts, ALLO has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allogene Therapeutics Inc (ALLO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.